Catherine Stehman-Breen
CIK: 0001702233
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Jun 5, 2026DYN
Dyne Therapeutics, Inc.
Award(A)DirectStock option (right to buy)
35.2K shares- - May 28, 2026TNYA
Tenaya Therapeutics, Inc.
Award(A)DirectStock Option (Right to buy)
120K shares- - Feb 9, 2026GBIO
Generation Bio Co.
Tender Offer(U)Direct4.8K shares- - Feb 9, 2026GBIO
Generation Bio Co.
Disposition(D)DirectStock Option (right to buy)
1.5K shares- - Feb 9, 2026GBIO
Generation Bio Co.
Disposition(D)DirectStock Option (right to buy)
1.9K shares- - Feb 9, 2026GBIO
Generation Bio Co.
Disposition(D)DirectStock Option (right to buy)
2.5K shares- - Feb 9, 2026GBIO
Generation Bio Co.
Disposition(D)DirectStock Option (right to buy)
6K shares- - Feb 9, 2026GBIO
Generation Bio Co.
Disposition(D)DirectStock Option (right to buy)
3K shares- - Feb 9, 2026GBIO
Generation Bio Co.
Disposition(D)DirectStock Option (right to buy)
5.2K shares- - Jun 4, 2025GBIO
Generation Bio Co.
Award(A)DirectStock Option (right to buy)
30K shares- - May 30, 2025DYN
Dyne Therapeutics, Inc.
Award(A)DirectStock option (right to buy)
35K shares- - May 29, 2025TNYA
Tenaya Therapeutics, Inc.
Award(A)DirectStock Option (Right to buy)
107.4K shares- - Oct 18, 2024TNYA
Tenaya Therapeutics, Inc.
Award(A)DirectStock Option (Right to buy)
34K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 5, 2026 |  DYN Dyne Therapeutics, Inc. | Award(A) Stock option (right to buy) | 35,152 | - | - | Direct |
| May 28, 2026 |  TNYA Tenaya Therapeutics, Inc. | Award(A) Stock Option (Right to buy) | 120,000 | - | - | Direct |
| Feb 9, 2026 |  GBIO Generation Bio Co. | Tender Offer(U) | 4,752 | - | $0 | Direct |
| Feb 9, 2026 | GBIO Generation Bio Co. | Disposition(D) Stock Option (right to buy) | 1,500 | - | - | Direct |
| Feb 9, 2026 | GBIO Generation Bio Co. | Disposition(D) Stock Option (right to buy) | 1,920 | - | - | Direct |
| Feb 9, 2026 | GBIO Generation Bio Co. | Disposition(D) Stock Option (right to buy) | 2,500 | - | - | Direct |
| Feb 9, 2026 | GBIO Generation Bio Co. | Disposition(D) Stock Option (right to buy) | 6,000 | - | - | Direct |
| Feb 9, 2026 | GBIO Generation Bio Co. | Disposition(D) Stock Option (right to buy) | 3,000 | - | - | Direct |
| Feb 9, 2026 | GBIO Generation Bio Co. | Disposition(D) Stock Option (right to buy) | 5,200 | - | - | Direct |
| Jun 4, 2025 | GBIO Generation Bio Co. | Award(A) Stock Option (right to buy) | 30,000 | - | - | Direct |
| May 30, 2025 | DYN Dyne Therapeutics, Inc. | Award(A) Stock option (right to buy) | 35,000 | - | - | Direct |
| May 29, 2025 | TNYA Tenaya Therapeutics, Inc. | Award(A) Stock Option (Right to buy) | 107,400 | - | - | Direct |
| Oct 18, 2024 | TNYA Tenaya Therapeutics, Inc. | Award(A) Stock Option (Right to buy) | 34,000 | - | - | Direct |
1-13 of 13 transactions
About Stehman-Breen Catherine
Stehman-Breen Catherine (SEC CIK 0001702233) files insider reports with the SEC as Director of Dyne Therapeutics, Inc. (DYN), Director of Tenaya Therapeutics, Inc. (TNYA) and Director of Generation Bio Co. (GBIO).
Signal8 holds 7 ownership filings by Stehman-Breen Catherine, all Form 4s, filed between Oct 21, 2024 and Jun 9, 2026. Those filings report 13 transactions, from Oct 18, 2024 to Jun 5, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Stehman-Breen Catherine's filings is in WALTHAM, MA.
Recent filings by Stehman-Breen Catherine
- Jun 5, 2026: Grant or award of DYN derivative securities (Form 4, code A).
- May 28, 2026: Grant or award of TNYA derivative securities (Form 4, code A).
- Feb 9, 2026: Tender of shares transaction of GBIO shares (Form 4, code U).
- Feb 9, 2026: Disposition to issuer transactions of GBIO derivative securities (6 lines, Form 4, code D).
- Jun 4, 2025: Grant or award of GBIO derivative securities (Form 4, code A).
Other insiders filing for Dyne Therapeutics, Inc. (DYN)
- Kerr Douglas, Head of R&D and CMO
- Posner Brian S, Director
- Friedl-Naderer Johanna, Chief Commercial Officer
- Cox John, CEO & President
- Rhodes Jason P, Director
- Lucera Erick, Chief Financial Officer